NEO · CYBN.NE
Cybin Inc.
CA$15.01-CA$0.21 (-1.38%)
Cybin Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
Loading market information…
TSX · HBP.TO · CAD
Stock price, earnings
Quote as of Oct 28, 2026, 04:39 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Helix BioPharma Corp.’s quoted price sits in the lower half of its reported 52-week range, 61.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Helix BioPharma Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the vascular epithelial growth factor receptor 2. Helix BioPharma has formed strategic alliances, including one with Moffitt Cancer Center to analyze L-DOS47's pharmacodynamics and assess the benefits of integrating it with immune checkpoint inhibitors. Another partnership, with ProMab Biotechnologies, Inc., is dedicated to creating innovative antibody and chimeric antigen receptor T-cell therapies to combat multiple myeloma. Furthermore, the company maintains licensing agreements with Xisle Pharma Ventures Trust and the National Research Council Canada.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$15.01-CA$0.21 (-1.38%)
Cybin Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
CA$4.98+CA$0.02 (+0.4%)
Quipt Home Medical Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.4% below the high.
CA$9.60+CA$0.57 (+6.31%)
Satellos Bioscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.42% below the high.
CA$1.66-CA$0.02 (-1.19%)
Cardiol Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.61% below the high.
CA$1.94-CA$0.08 (-3.96%)
Cannara Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.14% below the high.
$0.53+$0.01 (+2.72%)
Jushi Holdings Inc’s quoted price sits in the lower half of its reported 52-week range, 41.69% below the high.
CA$4.56+CA$0.00 (0.0%)
HLS Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.72% below the high.
CA$0.11CA$0.00 (0.0%)
Sernova Corp.’s quoted price sits in the lower half of its reported 52-week range, 45.0% below the high.
